In fact, on Feb. 4, Bloomberg reported that fellow life sciences conglomerate Danaher had expressed interest in purchasing Catalent at a "significant premium." Catalent ended Feb. 3 at $56.05 per ...

Catalent (CTLT) has also been the subject of takeover speculation, including from Danaher (DHR), though Bloomberg reported in April that the life-sciences company was no longer considering an ...

Medical equipment giant Danaher (DHR) will officially spin off its environmental-and-applied solutions segment later this month, and our plan is to remain invested in the soon-to-be standalone ...

Steve Rales. Steven M. Rales is an American businessman and film producer, and chairman of Danaher Corporation. He is listed as the 118th richest person in America, with a value of $3.2 billion.

The company, which has been the target of takeover ... Earlier this year, Danaher (DHR.N), which on Monday agreed to acquire Abcam, was reported as a possible suitor. Catalent, which is valued ...

The company, which has been the target of takeover interest ... Earlier this year, Danaher, which on Monday agreed to acquire Abcam, was reported as a possible suitor. Catalent, which is valued ...

Danaher, which on Monday agreed to acquire Abcam, was reported earlier this year as a possible suitor for Catalent. Merck KGaA last year expressed interest. (Reporting by Svea Herbst-Bayliss in ...

Danaher will now sell its GeneXpert test cartridge for $7.97 each to the Global Fund to Fight AIDS, Tuberculosis, and Malaria, as well as to some less-developed countries, according to a statement.

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments ...

The company, which has been the target of takeover interest ... Earlier this year, Danaher, which on Monday agreed to acquire Abcam, was reported as a possible suitor. Catalent, which is valued ...